cmf breast cancer

Release time ：Dec-24,2024

Breast cancer is a prevalent malignant neoplasm, and its therapeutic approaches typically encompass surgery, radiotherapy, chemotherapy, and other modalities. The CMF regimen, a frequently utilized chemotherapy protocol, consists of three medications: Cyclophosphamide, Methotrexate, and 5-Fluorouracil. This regimen is predominantly employed for the adjuvant treatment of patients with early-stage breast cancer to mitigate the likelihood of cancer relapse.

Within the CMF regimen, Cyclophosphamide induces cancer cell death by disrupting their DNA, Methotrexate halts cancer cell proliferation by inhibiting folic acid metabolism, and 5-Fluorouracil impedes the synthesis of RNA in cancer cells, thereby achieving therapeutic efficacy. The synergistic administration of these drugs can enhance treatment outcomes, although it may also elevate the potential for adverse effects.

Patients undergoing CMF regimen treatment may encounter side effects such as nausea, vomiting, alopecia, and oral mucositis. Consequently, it is imperative for patients to vigilantly monitor their health status and promptly communicate any discomfort to their physician. Additionally, patients should adhere to their doctor's recommendations for regular follow-ups to facilitate timely adjustments to the treatment plan. Throughout the treatment journey, maintaining a positive mindset and actively engaging with the physician's therapeutic strategies can optimize treatment outcomes.